mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2022-6-7-11mrj-1366Research ArticleЛЕКЦИЯLECTUREМикробиота как новый патогенетический фактор развития хронической гиперурикемии и подагры. Часть 2: терапия подагры и кишечная микробиотаMicrobiota as a new pathogenetic factor in the development of chronic hyperuricemia and gout. Part 2: gout therapy and the gut microbiotahttps://orcid.org/0000-0003-1191-5831ЕлисеевМ. С.EliseevM. S.

Елисеев Максим Сергеевич.

115522, Москва, Каширское шоссе, 34А

Maxim S. Eliseev.

34A, Kashirskoe Shosse, Moscow 115522

elicmax@yandex.ruhttps://orcid.org/0000-0001-8864-7623ХарламоваЕ. Н.KharlamovaE. N.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

https://orcid.org/0000-0002-5394-7869ЖелябинаО. В.ZhelyabinaO. V.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

https://orcid.org/0000-0002-6068-3080ЛилаА. М.LilaA. M.

Кафедра ревматологии РМАНПО МЗ РФ.

115522, Москва, Каширское шоссе, 34А; 125993, Москва, ул. Баррикадная, 2/1, стр. 1

Department of Rheumatology Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia.

34A, Kashirskoe Shosse, Moscow 115522; 2/1, Barrikadnaya Street, Build. 1, Moscow 125993

Научно-исследовательский институт ревматологии им. В.А. НасоновойРоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationНаучно-исследовательский институт ревматологии им. В.А. Насоновой; Российская медицинская академия непрерывного профессионального образования Минздрава РоссииРоссияV.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuing Professional Education, Ministry of Health of RussiaRussian Federation202217122022166711Copyright © Елисеев М.С., Харламова Е.Н., Желябина О.В., Лила А.М., 20222022Елисеев М.С., Харламова Е.Н., Желябина О.В., Лила А.М.Eliseev M.S., Kharlamova E.N., Zhelyabina O.V., Lila A.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/1366

В статье представлены современные данные о влиянии лекарственных препаратов для лечения подагры на состав и функцию микробиоты кишечника. Обсуждаются потенциальные возможности применения для профилактики и комплексной терапии подагры пре- и пробиотиков, терапевтический эффект которых может быть связан с их воздействием на синтез и кишечную экскрецию мочевой кислоты, а также с противовоспалительными свойствами. Подчеркивается необходимость дальнейших исследований в этой области.

The article presents current data on the effect of drugs for the treatment of gout on the composition and function of the intestinal microbiota. The potential possibilities of pre- and probiotics use for the prevention and complex therapy of gout are discussed, therapeutic effect may be associated with their impact on the uric acid synthesis and intestinal excretion, as well as with anti-inflammatory properties. The need for further research in this area is emphasized.

микробиотаподаграгиперурикемияпробиотикипребиотикифебуксостаталлопуринолmicrobiotagouthyperuricemiaprobioticsprebioticsfebuxostatallopurinolРабота выполнена в рамках фундаментального исследования «Разработка междисциплинарной персонализированной модели оказания помощи пациентам с аутовоспалительными дегенеративными заболеваниями (остеоартрит, остеопороз, саркопения, подагра, пирофосфатная артропатия) и мультиморбидностью (ожирение, сердечно-сосудистые заболевания)», номер темы: FURS-2022-004/ 1021051403074-2396.The investigation has been conducted within fundamental scientific topic "Development of an interdisciplinary personalized model of care for patients with autoinflammatory degenerative diseases (osteoarthritis, osteoporosis, sarcopenia, gout, pyrophosphate arthropathy) and multimorbidity (obesity, cardiovascular diseases)", topic number: FURS-2022-004 / 1021051403074-2396.ReferencesЧикина МН, Елисеев МС, Желябина ОВ. Практическое применение национальных клинических рекомендаций по лечению подагры (предварительные данные). Современная ревматология. 2020;14(2):97-103. doi: 10.14412/1996-70122020-2-97-103Chikina MN, Eliseev MS, Zhelyabina OV. Practical application of national clinical guidelines for the management of gout (preliminary data). Sovremennaya revmatologiya = Modern Rheumatology Journal. 2020;14(2): 97-103. (In Russ.). doi: 10.14412/1996-70122020-2-97-103Karkman A, Lehtimaki J, Ruokolainen L. The ecology of human microbiota: dynamics and diversity in health and disease. Ann N Y Acad Sci. 2017 Jul;1399(1):78-92. doi: 10.1111/nyas.13326. Epub 2017 Mar 20.Karkman A, Lehtimaki J, Ruokolainen L. The ecology of human microbiota: dynamics and diversity in health and disease. Ann N Y Acad Sci. 2017 Jul;1399(1):78-92. doi: 10.1111/nyas.13326. Epub 2017 Mar 20.O Sheridan P, Martin JC, Lawley TD, et al. Polysaccharide utilization loci and nutritional specialization in a dominant group of butyrate-producing human colonic Firmicutes. Microb Genom. 2016 Feb 9;2(2):e000043. doi: 10.1099/mgen.0.000043. eCollection 2016 Feb.O Sheridan P, Martin JC, Lawley TD, et al. Polysaccharide utilization loci and nutritional specialization in a dominant group of butyrate-producing human colonic Firmicutes. Microb Genom. 2016 Feb 9;2(2):e000043. doi: 10.1099/mgen.0.000043. eCollection 2016 Feb.Nicholson JK, Holmes E, Kinross J, et al. Host-gut microbiota metabolic interactions. Science. 2012 Jun 8;336(6086):1262-7. doi: 10.1126/science.1223813. Epub 2012 Jun 6.Nicholson JK, Holmes E, Kinross J, et al. Host-gut microbiota metabolic interactions. Science. 2012 Jun 8;336(6086):1262-7. doi: 10.1126/science.1223813. Epub 2012 Jun 6.Jumpertz R, Le DS, Turnbaugh PJ, et al. Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans. Am J Clin Nutr. 2011 Jul;94(1):58-65. doi: 10.3945/ajcn.110.010132. Epub 2011 May 4.Jumpertz R, Le DS, Turnbaugh PJ, et al. Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans. Am J Clin Nutr. 2011 Jul;94(1):58-65. doi: 10.3945/ajcn.110.010132. Epub 2011 May 4.Gordon JI, Dewey KG, Mills DA, Medzhi-tov RM. The human gut microbiota and undernutrition. Sci Transl Med. 2012 Jun 6; 4(137):137ps12. doi: 10.1126/scitranslmed.3004347.Gordon JI, Dewey KG, Mills DA, Medzhi-tov RM. The human gut microbiota and undernutrition. Sci Transl Med. 2012 Jun 6; 4(137):137ps12. doi: 10.1126/scitranslmed.3004347.Kashyap PC, Chia N, Nelson H, et al. Microbiome at the Frontier of Personalized Medicine. Mayo Clin Proc. 2017 Dec;92(12): 1855-64. doi: 10.1016/j.mayocp.2017.10.004.Kashyap PC, Chia N, Nelson H, et al. Microbiome at the Frontier of Personalized Medicine. Mayo Clin Proc. 2017 Dec;92(12): 1855-64. doi: 10.1016/j.mayocp.2017.10.004.Maiuolo J, Oppedisano F, Gratteri S, et al. Regulation of uric acid metabolism and excretion. Int J Cardiol. 2016 Jun 15;213:8-14. doi: 10.1016/j.ijcard.2015.08.109. Epub 2015 Aug 14.Maiuolo J, Oppedisano F, Gratteri S, et al. Regulation of uric acid metabolism and excretion. Int J Cardiol. 2016 Jun 15;213:8-14. doi: 10.1016/j.ijcard.2015.08.109. Epub 2015 Aug 14.Lin S, Zhang T, Zhu L, et al. Characteristic dysbiosis in gout and the impact of a uric acid-lowering treatment, febuxostat on the gut microbiota. J Genet Genomics. 2021 Sep 20; 48(9):781-91. doi: 10.1016/j.jgg.2021.06.009. Epub 2021 Jul 9.Lin S, Zhang T, Zhu L, et al. Characteristic dysbiosis in gout and the impact of a uric acid-lowering treatment, febuxostat on the gut microbiota. J Genet Genomics. 2021 Sep 20; 48(9):781-91. doi: 10.1016/j.jgg.2021.06.009. Epub 2021 Jul 9.Crane JK, Naeher TM, Broome JE, Boedeker EC. Role of host xanthine oxidase in infection due to enteropathogenic and Shiga-toxigenic Escherichia coli. Infect Immun. 2013 Apr;81(4):1129-39. doi: 10.1128/IAI.01124-12. Epub 2013 Jan 22.Crane JK, Naeher TM, Broome JE, Boedeker EC. Role of host xanthine oxidase in infection due to enteropathogenic and Shigatoxigenic Escherichia coli. Infect Immun. 2013 Apr;81(4):1129-39. doi: 10.1128/IAI.01124-12. Epub 2013 Jan 22.Sathisha KR, Khanum SA, Chandra JN, et al. Synthesis and xanthine oxidase inhibitory activity of 7-methyl-2-(phenoxymethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one derivatives. Bioorg Med Chem. 2011 Jan 1; 19(1):211-20. doi: 10.1016/j.bmc.2010.11.034. Epub 2010 Nov 18.Sathisha KR, Khanum SA, Chandra JN, et al. Synthesis and xanthine oxidase inhibitory activity of 7-methyl-2-(phenoxymethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one derivatives. Bioorg Med Chem. 2011 Jan 1; 19(1):211-20. doi: 10.1016/j.bmc.2010.11.034. Epub 2010 Nov 18.Guo Z, Zhang J, Wang Z, et al. Intestinal Microbiota Distinguish Gout Patients from Healthy Humans. Sci Rep. 2016 Feb 8; 6:20602. doi: 10.1038/srep20602.Guo Z, Zhang J, Wang Z, et al. Intestinal Microbiota Distinguish Gout Patients from Healthy Humans. Sci Rep. 2016 Feb 8; 6:20602. doi: 10.1038/srep20602.Chen RJ, Chen MH, Chen YL, et al. Evaluating the urate-lowering effects of different microbial fermented extracts in hyperuricemic models accompanied with a safety study. J Food Drug Anal. 2017 Jul;25(3):597-606. doi: 10.1016/j.jfda.2016.07.003. Epub 2016 Aug 3.Chen RJ, Chen MH, Chen YL, et al. Evaluating the urate-lowering effects of different microbial fermented extracts in hyperuricemic models accompanied with a safety study. J Food Drug Anal. 2017 Jul;25(3):597-606. doi: 10.1016/j.jfda.2016.07.003. Epub 2016 Aug 3.Suxian L, Zhang T, Zhu L, et al. Characteristic dysbiosis in gout and the impact of a uric acid-lowering treatment, febuxostat on the gut microbiota. J Genet Genomics. 2021 Sep 20;48(9):781-91. doi: 10.1016/j.jgg.2021.06.009. Epub 2021 Jul 9.Suxian L, Zhang T, Zhu L, et al. Characteristic dysbiosis in gout and the impact of a uric acid-lowering treatment, febuxostat on the gut microbiota. J Genet Genomics. 2021 Sep 20;48(9):781-91. doi: 10.1016/j.jgg.2021.06.009. Epub 2021 Jul 9.Chu Y, Sun S, Huang Y, et al. Metagenomic analysis revealed the potential role of gut microbiome in gout. NPJ Biofilms Microbiomes. 2021 Aug 9;7(1):66. doi: 10.1038/s41522-021-00235-2.Chu Y, Sun S, Huang Y, et al. Metagenomic analysis revealed the potential role of gut microbiome in gout. NPJ Biofilms Microbiomes. 2021 Aug 9;7(1):66. doi: 10.1038/s41522-021-00235-2.Yu Y, Liu Q, Li H, et al. Alterations of the Gut Microbiome Associated With the Treatment of Hyperuricaemia in Male Rats. Front Microbiol. 2018 Sep 19;9:2233. doi: 10.3389/fmicb.2018.02233. eCollection 2018.Yu Y, Liu Q, Li H, et al. Alterations of the Gut Microbiome Associated With the Treatment of Hyperuricaemia in Male Rats. Front Microbiol. 2018 Sep 19;9:2233. doi: 10.3389/fmicb.2018.02233. eCollection 2018.Yamanaka H, Taniguchi A, Tsuboi H, et al. Hypouricaemic effects of yoghurt containing Lactobacillus gasseri PA-3 in patients with hyperuricaemia and/or gout: A randomised, double-blind, placebo-controlled study. Mod Rheumatol. 2019 Jan;29(1):146-50. doi: 10.1080/14397595.2018.1442183. Epub 2018 Mar 9.Yamanaka H, Taniguchi A, Tsuboi H, et al. Hypouricaemic effects of yoghurt containing Lactobacillus gasseri PA-3 in patients with hyperuricaemia and/or gout: A randomised, double-blind, placebo-controlled study. Mod Rheumatol. 2019 Jan;29(1):146-50. doi: 10.1080/14397595.2018.1442183. Epub 2018 Mar 9.Kondratiuk VE, Tarasenko OM, Karmazina OM, Taranchuk VV. Impact of the Synbiotics and Urate-Lowering Therapy on Gut Microbiota and Cytokine Profile in Patients with Chronic Gouty Arthritis. J Med Life. 2020 Oct-Dec;13(4):490-8. doi: 10.25122/jml-2020-0065.Kondratiuk VE, Tarasenko OM, Karmazina OM, Taranchuk VV. Impact of the Synbio-tics and Urate-Lowering Therapy on Gut Microbiota and Cytokine Profile in Patients with Chronic Gouty Arthritis. J Med Life. 2020 Oct-Dec;13(4):490-8. doi: 10.25122/jml-2020-0065.Cleophas MC, Crisan TO, Joosten LA. Factors modulating the inflammatory response in acute gouty arthritis. Curr Opin Rheumatol. 2017 Mar;29(2):163-70. doi: 10.1097/BOR.0000000000000366.Cleophas MC, Crisan TO, Joosten LA. Factors modulating the inflammatory response in acute gouty arthritis. Curr Opin Rheumatol. 2017 Mar;29(2):163-70. doi: 10.1097/BOR.0000000000000366.Vieira AT, Galvro I, Amaral FA, et al. Oral treatment with Bifidobacterium longum 51A reduced inflammation in a murine experimental model of gout. Benef Microbes. 2015; 6(6):799-806. doi: 10.3920/BM2015.0015. Epub 2015 Aug 31.Vieira AT, Galvro I, Amaral FA, et al. Oral treatment with Bifidobacterium longum 51A reduced inflammation in a murine experimental model of gout. Benef Microbes. 2015; 6(6):799-806. doi: 10.3920/BM2015.0015. Epub 2015 Aug 31.Li M, Yang D, Mei L, et al. Screening and characterization of purine nucleoside degrading lactic acid bacteria isolated from Chinese sauerkraut and evaluation of the serum uric acid lowering effect in hyperuricemic rats. PLoS One. 2014 Sep 3;9(9):e105577. doi: 10.1371/journal.pone.0105577. eCollection 2014.Li M, Yang D, Mei L, et al. Screening and characterization of purine nucleoside degrading lactic acid bacteria isolated from Chinese sauerkraut and evaluation of the serum uric acid lowering effect in hyperuricemic rats. PLoS One. 2014 Sep 3;9(9):e105577. doi: 10.1371/journal.pone.0105577. eCollection 2014.Yang D, Yu X, Wu Y, et al. Enhancing flora balance in the gastrointestinal tract of mice by lactic acid bacteria from Chinese sourdough and enzyme activities indicative of metabolism of protein, fat, and carbohydrate by the flora. J Dairy Sci. 2016 Oct;99(10):7809-20. doi: 10.3168/jds.2016-11467. Epub 2016 Jul 21.Yang D, Yu X, Wu Y, et al. Enhancing flora balance in the gastrointestinal tract of mice by lactic acid bacteria from Chinese sourdough and enzyme activities indicative of metabolism of protein, fat, and carbohydrate by the flora. J Dairy Sci. 2016 Oct;99(10):7809-20. doi: 10.3168/jds.2016-11467. Epub 2016 Jul 21.Chang WC. Dietary intake and the risk of hyperuricemia, gout and chronic kidney disease in elderly Taiwanese men. Aging Male. 2011 Sep;14(3):195-202. doi: 10.3109/13685538.2010.512372. Epub 2010 Sep 20.Chang WC. Dietary intake and the risk of hyperuricemia, gout and chronic kidney disease in elderly Taiwanese men. Aging Male. 2011 Sep;14(3):195-202. doi: 10.3109/13685538.2010.512372. Epub 2010 Sep 20.Pereira FC, Berry D. Microbial nutrient niches in the gut. Environ Microbiol. 2017 Apr;19(4):1366-78. doi: 10.1111/1462-292013659. Epub 2017 Feb 3.Pereira FC, Berry D. Microbial nutrient niches in the gut. Environ Microbiol. 2017 Apr;19(4):1366-78. doi: 10.1111/1462-292013659. Epub 2017 Feb 3.Watzl B, Girrbach S, Roller M. Inulin, oligofructose and immunomodulation. Br J Nutr. 2005 Apr;93 Suppl 1:S49-55. doi: 10.1079/bjn20041357.Watzl B, Girrbach S, Roller M. Inulin, oligofructose and immunomodulation. Br J Nutr. 2005 Apr;93 Suppl 1:S49-55. doi: 10.1079/bjn20041357.Lin Z, Zhang B, Liu X, et al. Effects of chicory inulin on serum metabolites of uric acid, lipids, glucose, and abdominal fat deposition in quails induced by purine-rich diets. J Med Food. 2014 Nov;17(11):1214-21. doi: 10.1089/jmf.2013.2991. Epub 2014 Oct 14.Lin Z, Zhang B, Liu X, et al. Effects of chicory inulin on serum metabolites of uric acid, lipids, glucose, and abdominal fat deposition in quails induced by purine-rich diets. J Med Food. 2014 Nov;17(11):1214-21. doi: 10.1089/jmf.2013.2991. Epub 2014 Oct 14.Елисеев МС, Новикова АМ. Коморбидность при подагре и гиперурикемии: распространенность, причины, перспективы уратснижающей терапии. Терапевтический архив. 2019;91(5):120-28.Eliseev MS, Novikova AM. Comorbidity in gout and hyperuricemia: prevalence, causes, prospects of urate-reducing therapy. Terapevticheskii arkhiv. 2019;91(5):120-28. (In Russ.).Venuto C, Butler M, Ashley ED, Brown J. Alternative therapies for Clostridium difficile infections. Pharmacotherapy. 2010 Dec;30(12):1266-78. doi: 10.1592/phco.30.12.1266.Venuto C, Butler M, Ashley ED, Brown J. Alternative therapies for Clostridium difficile infections. Pharmacotherapy. 2010 Dec;30(12):1266-78. doi: 10.1592/phco.30.12.1266.Bernini LJ, Simao ANC, de Souza CHB, et al. Effect of bifidobacterium lactis HN019 on inflammatory markers and oxidative stress in subjects with and without the metabolic syndrome. Br J Nutr. 2018 Sep;120(6):645-52. doi: 10.1017/S0007114518001861. Epub 2018 Jul 30.Bernini LJ, Simao ANC, de Souza CHB, et al. Effect of bifidobacterium lactis HN019 on inflammatory markers and oxidative stress in subjects with and without the metabolic syndrome. Br J Nutr. 2018 Sep;120(6):645-52. doi: 10.1017/S0007114518001861. Epub 2018 Jul 30.Garcia-Arroyo FE, Gonzaga G, Munoz-Jimenez I, et al. Probiotic supplements prevented oxonic acid-induced hyperuricemia and renal damage. PLoS One. 2018 Aug 24; 13(8):e0202901. doi: 10.1371/journal.pone.0202901. eCollection 2018.Garcia-Arroyo FE, Gonzaga G, Munoz-Jimenez I, et al. Probiotic supplements prevented oxonic acid-induced hyperuricemia and renal damage. PLoS One. 2018 Aug 24; 13(8):e0202901. doi: 10.1371/journal.pone.0202901. eCollection 2018.Wan H, Han J, Tang S, et al. Comparisons of protective effects between two sea cucumber hydrolysates against diet induced hyperuricemia and renal inflammation in mice. Food Funct. 2020 Jan 29;11(1):1074-86. doi: 10.1039/c9fo02425e.Wan H, Han J, Tang S, et al. Comparisons of protective effects between two sea cucumber hydrolysates against diet induced hyperuricemia and renal inflammation in mice. Food Funct. 2020 Jan 29;11(1):1074-86. doi: 10.1039/c9fo02425e.Liu ZQ, Sun X, Liu ZB, et al. Phytochemicals in traditional Chinese medicine can treat gout by regulating intestinal flora through inactivating NLRP3 and inhibiting XOD activity. J Pharm Pharmacol. 2022 Jul 15; 74(7):919-29. doi: 10.1093/jpp/rgac024.Liu ZQ, Sun X, Liu ZB, et al. Phytochemicals in traditional Chinese medicine can treat gout by regulating intestinal flora through inactivating NLRP3 and inhibiting XOD activity. J Pharm Pharmacol. 2022 Jul 15; 74(7):919-29. doi: 10.1093/jpp/rgac024.Елисеев МС, Желябина ОВ. Рациональное использование рекомендаций по применению уратснижающей терапии: клинические примеры. Современная ревматология. 2022;16(3):85-90. doi: 10.14412/19967012-2022-3-85-90Eliseev MS, Zhelyabina OV. Rational use of recommendations for urate-lowering therapy: clinical examples. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2022; 16(3):85-90. (In Russ.). doi: 10.14412/19967012-2022-3-85-90Cole G. Evaluating development and production costs: tablets versus capsules. Pharmaceutical technology Europe. 1998;5:17-26.Cole G. Evaluating development and production costs: tablets versus capsules. Pharmaceutical technology Europe. 1998;5:17-26.Чикина МН, Елисеев МС, Желябина ОВ. Практическое применение национальных клинических рекомендаций по лечению подагры (предварительные данные). Современная ревматология. 2020;14(2):97-103. doi: 10.14412/1996-70122020-2-97-103.Chikina MN, Eliseev MS, Zhelyabina OV. Practical application of national clinical guidelines for the management of gout (preliminary data). Sovremennaya revmatologiya = Modern Rheumatology Journal. 2020;14(2): 97-103. (In Russ.). doi: 10.14412/1996-70122020-2-97-103.

The authors declare that there are no conflicts of interest present.